Summary of reports examined
| Reference | n/N; % (95% CI) | ||||
|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
| †† and **, probably the same study groups. | |||||
| Group 1, patients in whom the polyneuropathy of unknown cause preceded the antibodies screening tests: number of patients with polyneuropathy (N) and antibodies (n); group 2, patients in whom the polyneuropathy of unknown cause preceded biopsy to confirm or reject the diagnoses coeliac disease: number of patients with polyneuropathy (N) and proven coeliac disease by biopsy (n); group 3, controls who were screened for antibodies: number of controls (N) and antibodies (n); group 4, controls who underwent biopsy to confirm or reject the diagnosis coeliac disease: number of controls (N) and proven coeliac disease by biopsy (n); group 5, patients known with coeliac disease who were screened for polyneuropathy: number of patients with coeliac disease (N) and polyneuropathy (n). | |||||
| CI, confidence interval. | |||||
| Hadjivassiliou et al, 199620 | 7/20; 35 (15.4 to 59.2) | 1/20; 5 (0.1 to 24.9) | 6/50†; 12 (4.5 to 24.3) | 0/50; 0 (0.0 to 7.1) | |
| Rosenberg et al (current study) | 1/16; 6 (0.2 to 30.2) | 0/16; 0 (0.0 to 20.6) | |||
| Luostarinen et al, 199946 | 0/20; 0 (0.0 to 16.8) | ||||
| Chin et al, 200347 | 0/323; 0 (0.0 to 1.1) | ||||
| Hadjivassiliou et al, 200348 | 149/1200†; 12 (10.6 to 14.3) | ||||
| Fasano et al, 200349 | 27/2845; 0.9 (0.6 to 1.4) | ||||
| Grodzinsky et al, 199250 | 124/1866; 7 (5.6 to 7.9) | 7/1866; 0.4 (0.2 to 0.8) | |||
| Luostarinen et al, 200351 | 4/24; 17 (4.7 to 37.4) | ||||
| Pengiran et al, 200252 | 3/620*; 0.5 (0.1 to 1.4) | ||||
| Holmes et al, 199753 | 2/388*; 0.5 (0.1 to 1.8) | ||||
| Volta et al, 200254 | 1/159; 0.6 (0.0 to 3.4) | ||||